Process
- How we fill the gap
BioClarus Sits at the Intersection of Science, Strategy & Markets
- Indication prioritization & pipeline strategy
- Differentiation vs. Standard of Care (SOC)
- Regulatory feasibility assessment
- Clinical trial design (Phase 0–III)
- Target Product Profile (TPP) & Integrated Development Plan (IDP) refinement
Quantify The Opportunity
- Market sizing (TAM/SAM) & forecasting
- Patient journey mapping & segmentation
- Pricing & market access signals (US/Ex-US)
- Go-to-Market (GTM) models
- Asset valuation & DCF modeling
Communicate The Value
- Investor narratives & fundraising pitches
- Business Development (BD) opportunity identification
- Diligence support (buy-side & sell-side)
- M&A and IPO readiness
- S-1 / Prospectus support
Acquirers do not buy narratives alone. They buy de-risked opportunities. That means a company must understand what evidence, diligence materials, competitive analysis, commercial logic, and integration story a buyer will need before the company enters the room.
- Our Engagement Model
The BioClarus 6-Week Sprint
01
Foundation
Weeks 1–2
Stakeholder alignment & interviews
Data collection & review
Strategic gap analysis
02
Insights
Weeks 2–3
Market analysis & sizing
Competitive landscape mapping
Clinical-commercial alignment
03
Refinement
Weeks 4–5
Pricing & valuation analysis
Narrative development
Scenario modeling
04
Delivery
Week 6
Strategic recommendations
Investor / BD-ready materials
Final strategy deck
Extended engagements upon request for ongoing or fractional support & implementation
- Flexible Engagement Options
Right-Sized for Your Stage
Strategic Advisory
Focused guidance, executive workshops, and leadership sessions to align stakeholders on critical decisions.
Fractional Embedded Leadership
Senior executive embedded within your team (e.g., Fractional CCO) to drive commercial execution without the overhead of a full-time hire.
Project Implementation
End-to-end project delivery with a defined scope, timeline, and deliverables. Ideal for indication prioritization, TPP development, or market sizing.
Bespoke Ongoing Support
Continuous advisory retainer tailored to evolving needs. Provides flexible access to our team's expertise as your company grows.
- Appendix
Common Questions About Working with BioClarus
How quickly can BioClarus get started?
We can mobilize within 5–7 business days. Our structured onboarding process ensures immediate strategic alignment without a prolonged ramp-up period, allowing us to deliver actionable insights from week one.
Do you work with companies outside the US?
Yes. Our team has deep experience across US, EU, Japan, and APAC markets. We regularly support global market access planning, ex-US licensing deals, and international launch strategies tailored to local regulatory environments.
What makes BioClarus different from a fractional CXO service?
We offer integrated clinical-commercial-financial expertise under one roof. Unlike a single fractional executive, you get the judgment of a seasoned C-suite leader backed by a full team of specialists—providing broader capabilities without the overhead.
How is engagement pricing structured?
All engagements are custom-scoped based on your specific needs. We offer flexible models including project-based fees, monthly retainers, and fractional embedded leadership. Contact us for a no-commitment discovery call.
IPO readiness starts before the IPO window opens. The companies that move fastest when markets recover are often the ones that have already disciplined their story, governance, financial controls, risk factors, development milestones, and investor-facing narrative.